Literature DB >> 4697687

Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia.

H C Kwaan, S Silverman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4697687

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  8 in total

Review 1.  Pharmacological therapy of vascular malformations of the gastrointestinal tract.

Authors:  Andrew Szilagyi; Maged P Ghali
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

2.  Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).

Authors:  Kornelia E C Wirsching; Frank Haubner; Thomas S Kühnel
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-01-09       Impact factor: 2.503

Review 3.  The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients.

Authors:  Johnny Cai; Jessica Ribkoff; Sven Olson; Vikram Raghunathan; Hanny Al-Samkari; Thomas G DeLoughery; Joseph J Shatzel
Journal:  Eur J Haematol       Date:  2019-12-16       Impact factor: 2.997

4.  Functional Alterations Involved in Increased Bleeding in Hereditary Hemorrhagic Telangiectasia Mouse Models.

Authors:  Cristina Egido-Turrión; Elisa Rossi; Claudia Ollauri-Ibáñez; María L Pérez-García; María A Sevilla; José María Bastida; José Ramón González-Porras; Alicia Rodríguez-Barbero; Carmelo Bernabeu; José M Lopez-Novoa; Miguel Pericacho
Journal:  Front Med (Lausanne)       Date:  2022-05-19

Review 5.  Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective.

Authors:  Athena Kritharis; Hanny Al-Samkari; David J Kuter
Journal:  Haematologica       Date:  2018-05-24       Impact factor: 9.941

6.  Tamoxifen Therapy for Recurrent Mucosal Bleeding in Hereditary Hemorrhagic Telangiectasia.

Authors:  Stephanie Yung; Julie-Anne Bell; Jim Brooker
Journal:  J Hematol       Date:  2021-02-06

7.  Renal arteriovenous malformation demonstrated angiographically in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease).

Authors:  D A Cooke
Journal:  J R Soc Med       Date:  1986-12       Impact factor: 18.000

8.  An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.

Authors:  Hanny Al-Samkari; Raj S Kasthuri; Joseph G Parambil; Hasan A Albitar; Yahya A Almodallal; Carolina Vázquez; Marcelo M Serra; Sophie Dupuis-Girod; Craig B Wilsen; Justin P McWilliams; Evan H Fountain; James R Gossage; Clifford R Weiss; Muhammad A Latif; Assaf Issachar; Meir Mei-Zahav; Mary E Meek; Miles Conrad; Josanna Rodriguez-Lopez; David J Kuter; Vivek N Iyer
Journal:  Haematologica       Date:  2021-08-01       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.